Table 3 Other secondary outcomes over 12 weeks
Joint | Joint-specific questionnaires | LSM change from baseline (95% CI) | ||
|---|---|---|---|---|
DF − HA | Placebo | Difference | ||
Hip | N | 46 | 44 | |
Patient global assessment score (mm)a | −35.5 (−44.5 to −26.5) | −25.7 (−35.7 to −15.6) | −9.9 (− 17.9 to − 1.8) | |
Physician global assessment score (mm)a | − 27.6 (−35.3 to −19.8) | −23.8 (−32.3 to −15.2) | −3.8 (−10.6 to 3.0) | |
SF-36 summary score | ||||
MCS | 4.5 (1.8 to 7.3) | 4.6 (1.6 to 7.7) | −0.1 (−2.6 to 2.4) | |
RCS | 3.7 (−1.1 to 8.5) | 1.0 (−4.3 to 6.2) | 2.8 (−1.5 to 7.1) | |
PCS | 4.9 (0.3 to 9.4) | 0.8 (−4.3 to 5.8) | 4.1 (0.0 to 8.3) | |
EQ-5D | ||||
QOL score | 0.13 (0.07 to 0.19) | 0.06 (−0.00 to 0.13) | 0.07 (0.02 to 0.12) | |
VAS score | 17.4 (8.6 to 26.2) | 11.0 (1.1 to 20.9) | 6.4 (−1.8 to 14.6) | |
Ankle | N | 30 | 30 | |
Patient global assessment score (mm)a | −21.7 (−29.9 to −13.4) | −21.3 (−30.3 to −12.3) | −0.3 (−10.4 to 9.7) | |
Physician global assessment score (mm)a | −25.0 (−32.1 to −18.0) | −24.2 (−32.1 to −16.3) | −0.8 (−9.5 to 7.8) | |
SF-36 summary score | ||||
MCS | 3.7 (0.8 to 6.7) | 2.8 (−0.3 to 5.9) | 0.9 (−2.6 to 4.4) | |
RCS | −5.4 (−10.8 to 0.0) | −2.9 (−8.8 to 3.0) | −2.5 (−9.0 to 4.0) | |
PCS | −0.3 (−4.9 to 4.3) | −2.6 (−7.4 to 2.1) | 2.4 (−3.2 to 7.9) | |
EQ-5D | ||||
QOL score | 0.06 (0.01 to 0.12) | 0.06 (−0.00 to 0.12) | 0.00 (−0.06 to 0.07) | |
VAS score | 1.6 (−5.4 to 8.6) | 1.2 (−6.4 to 8.8) | 0.4 (−8.0 to 8.9) | |
Shoulder | N | 45 | 45 | |
Patient global assessment score (mm)a | −20.2 (−25.3 to −15.1) | −20.1 (− 25.3 to −14.8) | −0.1 (− 6.7 to 6.4) | |
Physician global assessment score (mm)a | −20.5 (− 25.6 to − 15.4) | −19.9 (− 25.2 to − 14.7) | −0.5 (−7.1 to 6.0) | |
SF-36 summary score | ||||
MCS | 3.3 (0.9 to 5.6) | 2.8 (0.4 to 5.2) | 0.5 (−2.5 to 3.5) | |
RCS | −1.4 (−4.9 to 2.2) | −0.2 (−3.9 to 3.5) | −1.2 (−5.7 to 3.3) | |
PCS | 0.3 (−2.6 to 3.2) | 2.3 (−0.7 to 5.3) | −2.0 (−5.7 to 1.7) | |
EQ-5D | ||||
QOL score | 0.06 (0.02 to 0.09) | 0.08 (0.05 to 0.12) | −0.03 (−0.07 to 0.02) | |
VAS score | 5.0 (−0.3 to 10.4) | 8.1 (2.7 to 13.6) | −3.1 (−9.8 to 3.7) | |
Elbow | N | 25 | 25 | |
Patient global assessment score (mm)a | −26.2 (−37.5 to −14.9) | −29.9 (−41.1 to −18.8) | 3.7 (−7.6 to 15.0) | |
Physician global assessment score (mm)a | −20.1 (−30.1 to −10.1) | −25.8 (−35.8 to −15.9) | 5.7 (−4.1 to 15.6) | |
SF-36 summary score | ||||
MCS | 1.4 (−2.9 to 5.8) | 3.7 (−0.6 to 8.0) | −2.3 (−6.6 to 2.0) | |
RCS | −5.6 (−10.5 to −0.8) | −1.9 (−6.7 to 3.0) | −3.8 (−8.6 to 1.1) | |
PCS | 4.6 (−0.4 to 9.6) | 1.0 (−3.8 to 5.9) | 3.6 (−1.4 to 8.6) | |
EQ-5D | ||||
QOL score | 0.02 (−0.05 to 0.09) | 0.06 (−0.01 to 0.13) | −0.04 (− 0.11 to 0.04) | |
VAS score | 1.8 (−6.5 to 10.2) | 3.9 (−4.4 to 12.3) | −2.1 (−10.6 to 6.4) | |